11 November 2024 | Monday | News
Image Source : Public Domain
Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunology, today announced the submission of an Investigational New Drug (IND) application to the Centre for Drug Evaluation of the National Medical Products Administration of China for HBM9378/SKB378, a fully human antibody targeting thymic stromal lymphopoietin (TSLP), for the treatment of chronic obstructive pulmonary disease (COPD).
COPD is a progressive respiratory condition with major complications, including cardiovascular risk, respiratory failure, and lung cancer. The disease imposes a significant and growing burden both in terms of healthcare costs and societal impact. There is an urgent need for new therapeutic options to alleviate the daily suffering of COPD patients and improve their quality of life.
"HBM9378/SKB378 has fully human sequences with less immunogenicity risk and better bioavailability compared to other TSLP-targeting competitors. Its long half-life optimization and outstanding biophysical properties further enhance its dosing and formulation advantages. We are confident in the potential of HBM9378/SKB378 and believe that this novel therapy can meet the diverse needs of COPD patients," said Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed.
Most Read
Bio Jobs
News
Editor Picks